SGLT2i and Incretin and CRTd.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.
Also called NCT03282136
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Registry
-
NCT03282136
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT03282136. Randomized; single masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2024-09-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2i and Incretin and CRTd.
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Heart Failure
- Intervention (Drug)
- Incretin Effect
- Intervention (Device)
- Cardiac Resynchronization therapy defibrillator device
- Intervention (Drug)
- SGLT-2 inhibitor
- Lead sponsor
- University of Campania Luigi Vanvitelli
Record details
- Record id
cardio:ct-nct03282136- Content hash
25aab018494c296002f5fd7db043a04558657967fcb49ea9389c045e1ea550b3